Recent developments include Vivani securing funding for its GLP-1 implant trial, pricing common stock offerings, advancing clinical trials, and corporate leadership changes.

• Vivani Medical secured funding for its GLP-1 implant trial as of March 2026 [N1].
• The company priced a common stock offering at $1.48 per share in January 2026 [N2][N3].
• Vivani's subsidiary Cortigent is presenting advanced brain-implant technology at NANS 2026 and is planned for spin-off as an independent Nasdaq company in 2025 [N4][N8].
• Anthony Baldor was appointed as CFO, succeeding Brigid Makes, in June 2025 [N6].
• Vivani reported successful initial data from the LIBERATE-1 Phase 1 study and secured $3 million in equity financing in May 2025 [N7].

Vivani Medical's innovative implantable drug delivery systems for GLP-1 receptor agonists could offer improved patient compliance and therapeutic outcomes in diabetes and obesity management. Clinical trial progress, including the LIBERATE-1 study and upcoming semaglutide implant trials, combined with secured funding and strategic spin-offs, support the company's advancement of its pipeline and commercialization efforts. The company's focus on addressing chronic diseases with high prevalence supports potential market opportunities.

Vivani Medical faces significant risks including the need for substantial additional capital to fund ongoing clinical trials and commercialization efforts. Regulatory approval processes are uncertain and may be delayed by government shutdowns or policy changes. Healthcare reform and drug pricing pressures, including Medicare price negotiation programs, may adversely affect future revenue potential. The company operates in a competitive and highly regulated environment with inherent risks of clinical trial failure and market acceptance challenges.

Vivani Medical's moat derives from its proprietary implantable drug delivery technology platform targeting chronic conditions with significant unmet medical needs. The company's focus on GLP-1 receptor agonist implants for diabetes and obesity positions it in a specialized niche with potential for differentiated treatment modalities. The planned spin-off of its Cortigent subsidiary may allow focused development of brain-implant technologies. However, as a clinical-stage company, Vivani faces typical biotech risks including regulatory hurdles, capital requirements, and competitive pressures from established pharmaceutical and medical device companies.

• Need for Additional Capital: Vivani requires substantial additional financing to continue product development and commercialization. Failure to secure funding on acceptable terms could delay or limit operations.
• Regulatory Risks: The company depends on FDA and other regulatory approvals, which may be affected by staffing, government shutdowns, and policy changes, potentially delaying product development.
• Market and Pricing Risks: Healthcare reform, drug pricing regulations, and reimbursement policies may reduce demand, pricing power, and profitability of future products.
• Operational Risks: Global economic disruptions, supply chain constraints, and health epidemics could adversely impact clinical trials and business operations.

• Vivani Medical, Inc. is a clinical-stage pharmaceutical company developing implantable drug delivery systems, including GLP-1 receptor agonist implants for type 2 diabetes and obesity treatment.
• The company has a subsidiary, Cortigent, focused on brain-implant technology, which is planned to be spun off as an independent Nasdaq-listed company in 2025.
• Vivani has conducted the LIBERATE-1 Phase 1 clinical trial assessing safety, tolerability, and pharmacokinetics of NPM-115 (exenatide implant) and is prioritizing development of NPM-139 (semaglutide implant).
• The LIBERATE-1 study was revised and regulatory approval was obtained to initiate the revised study in Australia.
• Vivani plans to initiate a Phase 1 clinical study of NPM-139 in the first half of 2026, pending regulatory clearance.
• The company has secured funding for the GLP-1 implant trial and has completed multiple equity financings, including private placements and registered direct offerings raising several million dollars.
• Vivani reported a net loss of $26.6 million for the fiscal year ended December 31, 2025, with basic and diluted EPS of -$0.43 per share.
• As of December 31, 2025, Vivani had $16.2 million in cash and cash equivalents, current assets of $17.9 million, and current liabilities of $6.6 million, resulting in a current ratio of 2.71 and a cash ratio of 2.46.
• The company faces risks related to the need for substantial additional financing to continue product development and commercialization efforts.
• Vivani operates in a highly regulated industry subject to FDA and other regulatory agency approvals, which can be affected by government shutdowns, staffing, and policy changes.
• The company is exposed to risks from global economic and geopolitical disruptions, including inflation, supply chain constraints, and health epidemics.
• Healthcare reform legislation and drug pricing policies, including Medicare price negotiation programs and executive orders aimed at lowering drug prices, may impact Vivani's future revenue and profitability.
• Vivani's expenses are expected to increase as clinical trials progress and commercialization activities commence, with potential for unanticipated costs due to regulatory requirements.
• The company has appointed Anthony Baldor as CFO, succeeding Brigid Makes.
• Vivani has announced and priced common stock offerings at $1.48 per share in early 2026.
• The company has reported positive preclinical data for its semaglutide implant in weight management.
• Vivani's business model includes developing implantable drug delivery technologies targeting chronic diseases such as diabetes and obesity.